Florian Rambow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7050371/publications.pdf

Version: 2024-02-01

23 papers	5,438 citations	331259 21 h-index	610482 24 g-index
27 all docs	27 docs citations	27 times ranked	10280 citing authors

#	Article	IF	Citations
1	Epithelialâ€toâ€mesenchymalâ€like transition events in melanoma. FEBS Journal, 2022, 289, 1352-1368.	2.2	54
2	A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nature Cell Biology, 2022, 24, 940-953.	4.6	52
3	CRISPR screens identify tumorâ€promoting genes conferring melanoma cell plasticity and resistance. EMBO Molecular Medicine, 2021, 13, e13466.	3.3	16
4	Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell, 2021, 39, 1135-1149.e8.	7.7	83
5	Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in Oncology, 2021, 11, 780654.	1.3	7
6	Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nature Cell Biology, 2020, 22, 986-998.	4.6	148
7	Disseminated Melanoma Cells Transdifferentiate into Endothelial Cells in Intravascular Niches at Metastatic Sites. Cell Reports, 2020, 31, 107765.	2.9	26
8	The long noncoding RNA NEAT1_1 is seemingly dispensable for normal tissue homeostasis and cancer cell growth. Rna, 2019, 25, 1681-1695.	1.6	39
9	Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming. Genome Research, 2019, 29, 1659-1672.	2.4	31
10	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes and Development, 2019, 33, 1295-1318.	2.7	203
11	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications, 2019, 10, 2723.	5.8	126
12	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Molecular Cancer Therapeutics, 2019, 18, 289-300.	1.9	25
13	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature Communications, 2018, 9, 4775.	5.8	70
14	Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nature Communications, 2018, 9, 2500.	5.8	92
15	Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, 2018, 174, 843-855.e19.	13.5	514
16	Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 2018, 558, 605-609.	13.7	177
17	A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature Cell Biology, 2017, 19, 1348-1357.	4.6	73
18	SCENIC: single-cell regulatory network inference and clustering. Nature Methods, 2017, 14, 1083-1086.	9.0	3,086

#	Article	IF	Citations
19	Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes. Cell Stem Cell, 2017, 21, 679-693.e6.	5.2	93
20	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. Journal of Clinical Investigation, 2017, 127, 2310-2325.	3.9	26
21	Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. Molecular Cell, 2016, 62, 890-902.	4.5	96
22	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget, 2016, 7, 71873-71886.	0.8	35
23	Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature Communications, 2015, 6, 6683.	5.8	365